Dr. Peter Rosen, MD
Claim this profileTower Hematology Oncology Medical Group
Studies Leukemia
Studies Lymphoma
2 reported clinical trials
2 drugs studied
Area of expertise
1Leukemia
CD22 positive
Stage III
Stage IV
2Lymphoma
CD22 positive
Stage III
Stage IV
Affiliated Hospitals
More about Peter Rosen, MD
Clinical Trial Related17 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 0 Active Clinical TrialsTreatments Peter Rosen, MD has experience with
- CAT-8015 Immunotoxin
- CAT-8015 Immunoxin
Breakdown of trials Peter Rosen, MD has run
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Rosen, MD specialize in?
Peter Rosen, MD focuses on Leukemia and Lymphoma. In particular, much of their work with Leukemia has involved CD22 positive patients, or patients who are Stage III.
Is Peter Rosen, MD currently recruiting for clinical trials?
No, Peter Rosen, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Peter Rosen, MD has studied deeply?
Yes, Peter Rosen, MD has studied treatments such as CAT-8015 Immunotoxin, CAT-8015 Immunoxin.
What is the best way to schedule an appointment with Peter Rosen, MD?
Apply for one of the trials that Peter Rosen, MD is conducting.
What is the office address of Peter Rosen, MD?
The office of Peter Rosen, MD is located at: Tower Hematology Oncology Medical Group, Beverly Hills, California 90211 United States. This is the address for their practice at the Tower Hematology Oncology Medical Group.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.